Connect with us
deals book
Advertisement
Polaris bank
Advertisement
Oando
Advertisement
Alpha
Advertisement
Hotflex
Advertisement
Binance
Advertisement
Advertisement
deals book
Advertisement
UBA
Advertisement
Patricia
Advertisement
Access bank
Advertisement
app

Blurb

UAC walks away from UPDC as turnaround efforts fail

UAC of Nigeria Plc has decided to spin off its stake in real estate subsidiary UPDC Plc, after turn around efforts failed.

Published

on

United Africa Company of Nigeria Plc

UAC of Nigeria Plc appears to have finally thrown in the towel in relation to troubled real estate subsidiary UACN Property Development Company (UPDC). In separate notices sent to the Nigerian Stock Exchange (NSE) yesterday,  the two firms laid out what they termed recapitalization and restructuring plans.  

The plans 

  •  UAC Nigeria will spin off its shareholding in UPDC to its shareholders. Figures from UPDC’s FY 2018 results show that UAC holds 64.16% or 1.6 billion of the 2.5 billion outstanding shares. 
  • This will however take place after UPDC carries out a N15.96 billion rights issue to repay its short term debt obligations. UPDC will be left with the outstanding balance of a N4.3 billion bond.  
  • UPDC’s interest in the UPDC Real Estate Investment Trust (UPDC REIT) will be unbundled to its shareholders.  UPDC owns about 40% of the REIT

The plans are however subject to the approval of shareholders, the Securities and Exchange Commission (SEC), and Nigerian Stock Exchange (NSE).  

The move by the conglomerate, was a somewhat unexpected one. At the last conference call held by the firm, management gave no inkling of its plans to spin off the firm.  

A problem child  

For shareholders of UAC, the move would be akin to removing a millstone from the firm’s neck. UPDC has been lossmaking for several years, despite efforts to turn it around.   

Results for the half year ended June 2019 show that the firm recorded a N1.2 billion loss. 2018 audited results show that the firm recorded a N15 billion loss. Auditors had expressed concern pertaining to the going status of the firm.  

This is despite the firm raising N5 billion through a rights issue in 2017 largely to deleverage its balance sheet. Parent company UAC, in 2017, also had to raise funds through a rights issue, with part of the proceeds used to take up its shares in the UPDC fund raise. 

UAC feels the pinch

The losses also affected UAC, as it incurred a N9.4 billion loss after tax, in FY 2018compared to a profit after tax of N1.3 billion made in the corresponding period of 2017. The poor result was largely due to losses in the UPDC, the company’s real estate division. Its share price nose dived and the stock was trading at numbers last seen in well over a decade.  

Board changes 

In August last year, UAC made several board changes.   

Hotflex

Folasope Aiyesimoju was appointed Chief Executive Officer (CEO). Aiyesimoju is the founder of Themis Capital Management, which in April 2018, took up a parent company UAC of Nigeria Plc.  

Niun Taiwo was also appointed as substantive Chief Operating Officer (COO). Prior to this, she had been Acting Managing Director since May 2017.   

Shareholder woes  

The material losses have naturally translated to massive capital losses for shareholders. The company’s share price slumped from N9.50 sometime in January 2015 to N0.88 as at the 30th of August, 2019, down 90.7%

UPDC 5 year price history

Shareholders who bought the stock at a peak price of N45.29 sometime in 2013 have suffered even more losses, as they have lost 98% of the value of their investments, if they held till date. 

 

 

Jaiz bank

UPDC 10 year price movement

Going forward 

UAC should witness an uptick in operations as the company can shift its focus to profitable segments. The stock’s share price which has been badly beaten in the last few years (down 52.3% in 2019 alone)) should witness an uptick. UAC gained 1.11% yesterday and over 15 million shares were traded.

The road to recovery for UPDC is still a long one, as the company would need a new majority stakeholder. Underperforming assets such as the Golden Tulip Hotel, will either have to be rejigged or sold.

Onome Ohwovoriole has a degree in Economics and Statistics from the University of Benin and prior to joining Nairametrics in December 2016 as Lead Analyst had stints in Publishing, Automobile Services, Entertainment and Leadership Training.He covers companies in the Nigerian corporate space, especially those listed on the Nigerian Stock Exchange (NSE).He also has a keen interest in new frontiers like Cryptocurrencies and Fintech. In his spare time, he loves to read books on finance, fiction as well as keep up with happenings in the world of international diplomacy.You can contact him via [email protected]

Click to comment

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Blurb

Dangote Sugar records revenue boost despite inflation and Apapa gridlock

Dangote Sugar has revealed it increased prices in the first quarter of 2021 to mitigate the problems of rising inflation and depreciation.

Published

on

Dangote Sugar proposes N18.2 billion as final dividend for 2020

One of Nigeria’s largest Sugar manufacturers, Dangote Sugar revealed it increased prices in the first quarter of 2021 to mitigate the problems of rising inflation and depreciation.

In a note to investors, the company revealed its recent 41.5% surge in revenues was due to an increase in sales volume as well as an uptick in price. In the first quarter of 2021, Dangote Sugar posted a revenue of N67.39 billion compared to N47.6 billion, the same period in 2020. The increase in price was driven by 5.7% pop in sales volume as the company sold 200,510 tonnes of sugar in the quarter compared to 189, 724 the same period in 2020.

But while sales value surged by 41.5%, volumes only rose 5.7% suggesting that price increase was a catalyst for the growth in revenue and the company alluded to this in its statement.

READ: Dangote set to earn N13 billion in dividend from his sugar business

Dangote Sugar’s performance

“Group sales volume increased in the quarter by 5.7% to 200,510 tonnes (2020: 189,724 tonnes). Growth continued to benefit from the sustained efforts to drive customer base expansion, several trade initiatives and investments. Group production volume also increased by 4.3% to 200,783 tonnes (2020: 192,584 tonnes) due to our operations optimization strategy despite the challenges of the Apapa traffic situation. Group revenue increased by 41.5% to N67.39 billion (2020: N47.64 billion). Growth in revenue advanced ahead of volume growth due to pricing benefits. Gross profit increased by 41.8% to N18.04 billion (2020: N12.72 billion) on account of better topline performance. EBITDA increased by 34.7% to N17.02 billion (2020: N12.64 billion) on account of increased earnings. Group profit after taxation for the period increased by 30.3% to N8.30 billion (2020: N6.37 billion) reflecting management’s unrelenting drive to deliver consistent shareholder value.”

The company also explained it had no choice but to increase prices because of the impact of the 2020 devaluation, higher inflationary environment, port congestion issues and a rise in global sugar prices. The company imports raw sugar from Brazil, under the government’s backward integration plan.

“We have continued to witness high cost of raw materials, energy costs and other input costs due to rising inflation and FX rate fluctuation. Further cost escalation is anticipated in the year as inflationary pressure mounts,” the company said.

READ: Dangote Sugar yearly revenue surge by 33%, announces a dividend of N1.50

Hotflex

Dangote vs BUA Sugar Scarcity Controversy

Just last month, the company’s adversary and competitor BUA Group accused Dangote Sugar of conniving with Flour Mills of Nigeria (FMN) in price-fixing and arbitrary collusion to create sugar scarcity and keep the price of the commodity high.

This triggered Dangote Sugar and FMN into issuing a joint press statement denying the accusations.

The allegation made by BUA was triggered by a joint letter written by John Coumantaros of FMN Plc and Aliko Dangote of Dangote Industries Limited, reporting key developments in the Nigerian Sugar Industry to the Minister of Industry Trade and Investment, Niyi Adebayo.

The duo in the letter dated January 28, 2021, pointed out how BUA’s new sugar refinery in Port Harcourt may lead to a spike above the import quota as stipulated in the National Sugar Master Plan (NSMP), and how BUA’s investment in the sugar industry via the new refinery is non-compliant to the undertakings under its Backward Integration Programme, in line with local production.

READ: Dangote’s stakes in his sugar enterprise has earned him N90 billion in 365 days

BUA’s response however led to an immediate reply by the duo of Dangote Sugar and Flour Mills of Nigeria.

“In line with this, the Dangote Sugar Refinery wishes to vehemently refute the allegations and assertions made by BUA Sugar Refinery as they are not only false but defamatory, malicious and libellous, as they were geared at tarnishing the good name and brand of Dangote Sugar Refinery Plc and Dangote Industries Limited.”

Jaiz bank

The Group Managing Director, Mr Ravindra Singhvi, explained that the Dangote Group is socially responsible and considers price-fixing to be unethical and disastrous to the nation’s economy, and as such, the allegations made by BUA is highly mischievous and defamatory and should be considered a malicious attempt to smear the reputation of DSR.

“DSR does not engage in artificial price manipulation of its products, either during the Holy month of Ramadan or at any other time. We have never ever increased the price of our food items or commodities during the Holy month of Ramadan in the history of our operations,” Ravindra Singhvi said.

Outlook for Dangote Sugar

Despite the operational headwinds, the company insist it is on track to improve its operations and seek growth in its sugar sales volumes. It also recently received approval from the government to revise its local sugar production targets to 550,000 metric tonnes annually from over 1 million metric tonnes annually.

“Despite these uncertainties, achievement of our Sugar for Nigeria Backward Integration Project goal remains a key priority, though we anticipate increase in cost to completion in Naira-terms and some delays in Letter of Credit establishment for the importation of plant and equipment. The focus is to achieve the Federal Government’s revised sugar production target of 550,000 metric tonnes annually by 2024. We remain confident of the huge benefits the Backward Integration Programme would deliver and the positive impacts it will have on the economy.”

Find out why Dangote Sugar is recommended as a buy in our Stock Select Portfolio Newsletter? Click here.

Continue Reading

Blurb

GlaxoSmithKline in big trouble as losses mount

The results were less than impressive with several key indicators showing a year-on-year decline.

Published

on

GSK Consumer Nigeria Plc records 3.34% increase in 2020 9M revenues.

GlaxoSmithKline Consumer Nigeria Plc (“GSK Plc” or “the Company”) is a public limited liability company with 46.4% of the shares of the Company held by Setfirst Limited and Smithkline Beecham Limited (both incorporated in the United Kingdom), and 53.6% held by Nigerian shareholders.

The ultimate parent and controlling party is GlaxoSmithKline Plc, United Kingdom (GSK Plc UK). The parent company controls GSK Plc through Setfirst Limited and SmithKline Beecham Limited.

The Company recently published its unaudited first quarter (Q1) 2021 consolidated financial statements for the period ended 31 March 2021.

READ: GSK Consumer Nigeria Plc records 3.34% increase in 2020 9M revenues

The results were less than impressive with several key indicators showing a year-on-year decline. For example, Group revenue (turnover) declined from ₦4.99 billion in Q1 2020 to ₦3.46 billion in Q1 2021 a drop of over 30.66%. The revenue drop was due to a sharp decline in the local sale of its healthcare products.

Total loss after tax as of Q1 2021 was ₦238.07 million compared to a profit after tax of ₦113.47 million for the same period to Q1 2020.

The company is essentially divided into two segments viz: Consumer Healthcare and Pharmaceuticals. While the Healthcare segment was largely profitable in Q1 2021 (making a profit before tax of ₦ 8.73 million by March 31, 2021, the pharmaceuticals segment made a loss of ₦262.93 million in the same period.

READ: GlaxoSmithKline Nigeria announces changes in its board

Hotflex

The Consumer Healthcare segment of the company consists of oral health products, digestive health products, respiratory health products, pain relievers, over the counter medicines, and nutritional healthcare; while the pharmaceutical segment consists of antibacterial medicines, vaccines, and prescription drugs. While goods for the consumer healthcare segment are produced in the country, the pharmaceuticals are all imported.

The largely imported pharmaceutical products are thus exposed to the vagaries of foreign currency fluctuations coupled with a negligible to no revenue from the foreign sale of its healthcare products (same as in Q1 2020) as it barely exports its products out of the country.

The cost of importing the antibacterial, vaccines and prescription drugs, and the significant local operating expenses wiped off the marginal gross profits made by the pharmaceutical segment of the company. In effect, the gross profit of ₦508.12 million made by the pharmaceutical segment of the company was eliminated by an operating expense of ₦735.7 million and this resulted in a net loss for the pharmaceutical segment of the business.

READ: Nigerian Breweries posts N7.66bn as Q1 2021 profit, shares gain 2.2%

Apart from the impact of imported pharmaceutical products as already discussed, other issues that affected the company’s Q1 2021 results and are likely to continue to affect its performance in future include:

  1. A limited product mix that has only the likes of Macleans and Sensodyne (Oral Healthcare); Pain relievers (Panadol and Voltaren); Digestive Health (Andrews Liver Salt); and Respiratory Health (Otrivin and Panadol Cold and Catarrh) all within the Consumer Healthcare segment.
  2. Increased competition, particularly from local pharmaceutical manufactures of similar over the counter medicines and other prescription medications and vaccines.

In addition, in October 2016, GSK Plc divested its drinks bottling and distribution business that manufactures and distributes Lucozade and Ribena in Nigeria, and other assets including the factory used for the drinks business to Suntory Beverage & Food Limited. The loss in revenue from these popular brands continues to impact its topline.

GlaxoSmithKline (GSK) is a global healthcare company and is well-known and acknowledged for its pioneering role in discovering and distributing vaccines for the likes of hepatitis A and B, meningitis, tetanus, influenza, rabies, typhoid, chickenpox, diphtheria, whooping cough, cervical cancer and many more.

Jaiz bank

It is also renowned for its manufacture and distribution of prescription medicines such as antibiotics and treatments for such ailments as asthma, HIV/AIDS, malaria, depression, migraines, diabetes, heart failure, and digestive disorders.

Perhaps GSK Plc’s fortunes may change if the company is able to obtain the parent company’s licence to manufacture GSK-owned vaccines and prescription medicines within the country while also exploring the possibility of extending the sale of its products outside the shores of the country.

Since different expertise is required for vaccines and prescription drug manufacture and distribution as compared to manufacture and sale of consumer healthcare products, perhaps another alternative may be for the company to create two separate companies with one company being a 100% vaccines and prescription drug pharmaceutical manufacturing and distribution company while the second company specializes entirely in the manufacture and sale of consumer healthcare products.

As a result of the Q1 2021 performance, the company’s earnings per share (EPS) dropped to -20 kobo compared to the 9 kobo earnings per share reported in Q1 2020. At the start of 2021, GSK Plc’s share price was ₦6.90 but the company has since lost over 10% of its price valuation as the company’s share price closed at ₦6.20 on April 30, 2021.

Continue Reading

  





Nairametrics | Company Earnings

Access our Live Feed portal for the latest company earnings as they drop.